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1. Introduction 
Prostate biopsy is a motor, driving force and entrance ticket for dealing with parade 
discipline in urology of recent years – prostate cancer. Therefore it receives a lot of attention 
and standard techniques are constantly challenged by new developments. Enormous 
amount of literature seem to have addressed all possible aspects regarding prostate biopsy. 
This chapter focuses less on historical overview but mainly on recent developments, 
controversies and questions. 
Prostate cancer has already become leading cancer among males in developed world (Jemal et 
al., 2011), second reason for death due to cancer among men in US (Jemal et al., 2010) and third 
in Europe (Malvezzi et al., 2011). Future is looking even more serious – numbers are expected 
to rise much further, as recently predicted in Canadian forecast analysis (Quon et al, 2011). The 
authors claim expected estimates of increase in prostate cancer cases should not be limited 
only to aging of population, which is huge itself and is expected to cause 39% increase in 
prostate cancer cases. At least three further factors should be taken into account. First and most 
important is lowering of PSA threshold for biopsy. It seems the move of decreasing PSA cutoff 
from 4 to 2.5 is getting from university centers to every urologist's and generalist's office (this 
is especially important as they are the ones who pick and refer patients to urologists for 
biopsy). Increase in number of people, referred to biopsy for this reason is estimated to be 
much greater compared to aging of population and may increase prostate cancer incidence by 
200%. If it will increase prostate cancer incidence by 200%, increase in number of biopsies 
should be disproportionally higher, as biopsies have lower yield for this new target population 
with PSA values between 2.5 and 4. PSA screening is creating at present a lot of debate, it is a 
very hot topic and there are very strong opponents and supporters. Introduction of formal 
screening would of course increase burden of cancer and burden of biopsy. It is at present 
unlikely to happen, probably because people who decide on health policies and their advisers 
do not meet, treat and care for people with advanced prostate cancer. But, call it case finding 
or however one prefers, a “non-formal” screening programs are actually already available in 
many health systems, not only in selected first adopters, like Tyrol in Austria (Oberaigner et 
al., 2006), but also for example in Slovenia, where every general practitioner has available extra 
funds for PSA measurement on all of his male patients, every two years. Extent of “non-
formal” screening programs can be seen from well-known PLCO trial, where control, 
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supposedly non-screened arm had 50% screening in comparison to intervention arm, 
supposedly “screened”, where the rate was approximately 85% (Andriole et al., 2009). Some 
do not believe into usefulness of screening (Miettinen, 2010) and results of studies, which 
clearly show improved survival and necessity for screening, for example of European 
Randomized Trial of Screening for Prostate Cancer (Schröder et al., 2009). Despite those 
doubts, screening in one way or another is in fact increasingly taking place in every-day life. 
Further increase in screening is expected because recent analyzes of prostate screening studies 
seem to greatly reduce predicted numbers needed to screen and numbers needed to treat to 
save a life in prostate cancer and dispel previous doubts about usefulness of screening 
(Crawford et al., 2011) and treatment (Bill-Axelson et al., 2011). 
Last reason for estimation of huge increase in prostate cancer cases expected in the next decade 
is stated (Quon et al., 2011) as “improved sensitivity of prostate biopsy”. Will this really 
happen? This review will summarize some of the present developments in this field. If this is 
really the case, it may be at least one good sign, sign of relief: with improved biopsy specificity, 
number of repeat biopsies, which at present already represent significant burden and may also 
represent group of patients with higher risk for biopsy-related complications, may decrease. 
Prostate biopsy aims to detect prostate cancer with as little problems and sequela as 
possible. Further, it aims to predict prognosis of detected cancer, therefore sampling must 
not only take any cancer, but representative cancer tissue samples from possibly all cancer 
focuses in the prostate. Third goal of modern prostate biopsy is to guide targeted therapy, 
which is expected to rise with increased number of lower stage cancers detected. 
2. Selection of biopsy candidates 
Only main criteria, which are in clinical use or are available and may be used in Europe in 2011 
are included here and they are: 3 PSA's (total, free and -2proPSA), urine marker (PCA3), race, 
family history, previous biopsy technique and result, age and life expectancy. 
There are markers, which were proposed and also used in the past, but are now outdated, 
like cPSA and other PSA's, not mentioned above. There are markers, which may become 
very useful in the future, but are at present not ready yet (for example SNP's and other 
genetic data or new urine markers, which may use advantage of being excreted and 
therefore no aggressive rectal prostate massage would be necessary (Pandha et al., 2011)). 
Should we really biopsy all men with PSA above 2.5? Obviously we do not want to do that. 
It remains unresolved task, how should we select between those who would benefit from 
biopsy even earlier, at PSA 1, from those who do not need biopsy at PSA 10. 
2.1 PSA's 
Prostate specific antigen, during history of its discovery named with other names, for 
example semenogelase, is an androgen-regulated serine protease (EC 3.4.21.77), human 
tissue kallikrein 3 (Balk et al, 2003). Gene is located on 19q13.4. Mainly it is produced in 
secretory epithelial cells in prostate acini and ducts and secreted into lumen. Its function 
is in ejaculate liquefaction.  
PSA is expressed in preproPSA form (17 aminoacid leading peptide), excreted into prostate 
lumen as proPSA (7 aminoacid propeptide on N-terminal) and activated by trypsine-like 
human kallikrein 2 (hK2), which is expressed on prostate secretory epithelial cells (Balk et.al, 
2003). ProPSA can undergo cleavage at position -7, removing 7 aminoacid propeptide to 
form active PSA. ProPSA cleavage can also occur at positions -5 or -2. Those PSA isoforms 
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are not catalytically active. Active PSA in part undergoes further degradation/internal 
cleavage by different proteases, thereby also forming inactive PSA. In seminal plasma 
approximately 30% of PSA is in active form. Remaining PSA represents different forms of 
inactive PSA. Some PSA (all forms) leaks to circulation and can be measured in serum. 
Active form of PSA in serum binds (complexes) to protease inhibitors, mostly to alpha1-
antichymotrypsin (ACT). It represents main part of total serum PSA (70-90%) and can be 
measured as cPSA. Catalytically inactive PSA forms circulate freely in serum as they are not 
complexed to ACT or other inhibitors. This fraction represents main result of free PSA assay. 
Antibodies were also developed for measuring serum concentrations of specific PSA 
isoforms, for example [-5]pro PSA and [-2]proPSA. Assays which measure total PSA aim at 
detecting all isoforms, active (complexed) and inactive PSA.  
As prostate cancer characteristic is disruption of basal cell layer and basement membrane, 
this allows increased amount of PSA and its isoforms to enter circulation (Balk et al, 2003). 
Free PSA fraction is decreased in serum of cancer patients. It is hypothesized there is 
relatively less free PSA in serum in cancer patients because more PSA enters circulation 
directly and complexes immediately to protease inhibitors. As there is less exposure of PSA 
to luminal and seminal fluid proteases, there is less chance for inactivating and producing 
inactive, free PSA. ProPSA isoforms are increased in serum of prostate cancer patients. Two 
hypotheses aim to explain this. One believes there is decreased cleavage of proPSA by hK2 
in prostate cancer tissue (Balk et al., 2003). Other hypothesis believes proPSA isoforms are 
increased in cancer as a result of increased proPSA production from benign looking cancer 
associated areas in prostate gland (Makarov et al., 2009).  
Higher serum PSA values were related to prostate cancer in 1980-ties. Hybritech, first 
commercial PSA measurement kit manufacturer, identified in a small study in 1986 in their 
sample 99% of tested men (different ages) had PSA below 4 and suggested this value as a 
cut-off. With this in hand, Catalona conducted a trial and published in 1991: 8% of tested 
men (mean age 68) had PSA values above 4, 22% of those with PSA between 4 and 10 had 
prostate cancer detected on sextant biopsy (and 67% among those with PSA above 10). 
Biopsy was performed using 18G needle. PSA was independent prognostic factor and 
positive DRE increased chance of positive biopsy (Catalona et al., 1991). 20 years later – we 
made a progress – now we do 12 core biopsies, use PSA cut-off 2.5 and use some other PSA 
derivatives to help in decisions. This modifies our outcomes a few percentages here and 
there, but main achievement, decrease in mortality due to prostate cancer, which was, after 
two decades of doubt, finally recently confirmed by a few large independent trials from 
both US and EU (see Introduction), was a result of a twenty years old approach, which is, 
with all its drawbacks and deficiencies, still valid and widely practiced around the world.  
Inadequacy of PSA cut-off value of 4 was in depth explained by publication of results of 
control biopsies in prostate cancer prevention trial (Thompson et al., 2004). They found, 
among men in age range 62 to 91, median 69, 6.6% of cancers among those with PSA 0.5 or 
less and 12.5% among them with Gleason 7 or more (=0.8% of all men with median age 69 
with PSA below 0.6 had important cancer). Among men with PSA of 1.1 to 2.0, cancer was 
found in 10% and 10% of those had Gleason 7 or more (=1% of all men with PSA between 1 
and 2, median age 69, had Gleason 7 or higher prostate cancer). For PSA 2-3, the percentage 
of Gleason 7 or more among all tested was 4.6% and for PSA 3-4 it was 6.7%. Those numbers 
were found in a prescreened population and with sextant biopsy. Now it is believed those 
numbers are still accurate for overall cancer presence, but for Gleason 7 or higher cancers in 
general referral population, real numbers are about twice those estimates. Several thoughts 
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follow from this data. One is related to high percentage of high grade cancers in population 
with median age 69 and relatively low PSA values. Once upon a time, it was suggested we 
should not measure PSA in men above 70. Should we now turn this completely around and 
biopsy all men with life expectancy of 10 yeas or more at the age of 70 irrespectively of their 
PSA? Or should we use other tests, like PSA isoforms derivatives?  
Free PSA is measured to calculate fraction towards total PSA value, which is expressed as 
percentage. In PSA ranges between 4 and 10, with % free PSA below 10%, probability for 
biopsy detected prostate cancer in DRE negative patients was 56% and with % free PSA 
above 25% probability of cancer was only 8%. In PSA range between 2.5 and 4, with % free 
PSA below 10%, probability of cancer was 46% and with % free PSA above 20% probability 
of cancer was 8% (Catalona et al., 1998).  
[-2]proPSA or p2PSA is new kid on the block, which is not yet universally available or 
accepted. It seems it will become next widely used PSA derivative, which is also used 
together with free PSA value (p2PSA/freePSA) or together with total and free PSA as value, 
calculated as p2PSA/freePSA times square root of total PSA and proprietary named by 
Beckman Coulter (Brea, California, USA) as PHI – prostate health index. Cut-off values for 
biopsy decisions using %p2PSA (p2PSA/free PSA) and PHI are not yet universally accepted 
and differ with regard to free PSA and total PSA calibration method (Hybritech or WHO), 
but it seems PHI values above 40 or 45 indicate high and below 21 low risk of prostate 
cancer. PHI of more than 48.5 was reported as 43% specific at 90% sensitive for detecting 
prostate cancer at initial prostate biopsy (Guazzoni et al., 2011). Another study reported PHI 
values above 34.2 to show increased probability for high risk disease (Isharwal et al., 2011). 
PHI was shown to indicate development of prostate cancer years before biopsy and 
correlated well with grade of future prostate cancer (Bektic et al., 2010). On negative side, 
using p2PSA compared to free PSA using ROC curves at area of high sensitivity (if we are to 
find cancer), increase in performance may seem marginal. 
PSA density and different variants (PSA density of transitional zone etc), calculated from 
total PSA value and measurement of prostate volume using transrectal ultrasound, were in 
the past extensively evaluated. Drawback is variability of prostate volume measurements, 
need for this additional investigation and low sensitivity (Pepe et al., 2009). One example of 
cutoff value was density above 0.15 ng/ml PSA /ml prostate volume indicating higher risk 
of cancer. It may represent additional useful piece of information, also for example 
regarding prediction of disease course for patients on watchful waiting (Kotb et. al, 2011).  
PSA velocity was in recent years proposed as another potentially helpful tool in picking 
cancers or high-risk cancers. Cutoff value of 0.35 ng/ml/year was proposed when total PSA 
values are less than 4. This may need adjustment for race (Tang et al., 2011). Although some 
doubts about value of PSA velocity in biopsy decisions were posed from analysis of PCPT 
trial data (Vickers et al., 2011), there are suggestions a lot of clinically important cancers in 
younger men may be detected by regularly and meticulously following and analyzing 
sequential PSA values (Bektic et al., 2011).  
PSA values increase with age due to BPH. This became known early after PSA test 
introduction and “age-specific” PSA values were suggested. For Caucasian Americans, 
median, 75th and 95th percentiles of PSA were for age group 40-49 – 0.7, 1.0 and 2.1, for 50-59 
age group 1.0, 1.6 and 3.6, for 60-69 age group 1.4, 2.5 and 4.3, for 70-79 decade 1.8, 3.5 and 
5.8 (Morgan et al., 1996). One approach of integrating age specific PSA values in prostate 
biopsy decisions may be using as cutoff half of age-specific 95th percentile PSA value 
together with %free PSA below 18%, which was in part used in Innsbruck (Tyrol, Austria). 
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High increase of PSA with infection or any irritation of prostate is well known and 
sometimes antibiotic or anti-inflammatory treatment is suggested and repeat measurement. 
PSA decreases in high body-mass index-correction and decreased of cutoff values may be 
needed (Pater et al., 2011). Diseases (liver cirrhosis) and medications (NSAID's, thiazides 
and statins) may also decrease PSA values (Nieder et al., 2011). If using free PSA values as 
trigger for biopsy decisions, it may be important to note that use of herbal products, like 
Serenoa repens, may (artifically?) increase free PSA values. 
2.2 Age and life expectancy 
Risk of prostate cancer significantly increases with age. Age is significant independent 
predictor of high risk prostate cancer. Although we need age as a criterion (we do not start 
to think about prostate cancer before age of 40 or 35), it is clear age could not be the only 
factor which would preclude decisions about PSA measurement, digital rectal exam and 
biopsy. Age is only one parameter in estimation of life expectancy. Life expectancy, not age, 
is crucial factor in decisions regarding prostate cancer screening interventions. Age does 
increase probability of cancer and cancer related death and therefore higher age – for 
example 75 years or more (with additional criterion of more than 10 years life expectancy) 
means strong indication in-favor of PSA screening and prostate biopsy. It is true that not all 
men at age 75 or more have more than 10 years of life expectancy, but significant number 
have and for them, prostate cancer screening is most useful and fruit bearing (much higher 
yield compared to younger men). This thinking is in strong contrast to past belief (and even 
now supported by some outdated recommendations of non-urological organizations), when 
PSA testing was not recommended generally for all older men.  
2.3 Digital rectal exam 
Digital rectal exam remains important part of prostate evaluation (Gosselaar et al., 2008). 
Although still on occasion declined by a patient and despite hopes PSA or any other method 
would completely replace it (Schroder et al., 1998), one still finds from time to time a case, 
where PSA is low and DRE is suspicious. For such a patient, next year, when PSA has 
increased, may be (and cases were confirmed it was) too late. Although after many 
suspicious DRE's biopsy comes negative, we are more and more aware of the fact that 
prostate cancer may progress without PSA increase. DRE can estimate sphincter tone, in a 
way prepare patient for biopsy, if needed, on occasion register some other, non-urological 
pathology and appreciate prostate size, which may give different dimension compared to 
ultrasound impression. DRE is necessary for sampling prostate cells in post-massage urine – 
at present for PCA3 only, but in the future maybe also for other markers. DRE is necessary 
for clinical staging of prostate cancer. DRE is limited, it can not palpate whole gland, but at 
present it is here to stay (Yossepowitch, 2008). 
2.4 PCA3 
Comparison of mRNA expression patterns of prostate cancer and benign tissues identified 
significantly different expression of non-coding mRNA sequence, first called DD3 
(Bussemakers et al., 1999) and later renamed PCA3. Technology (a variant of quantitative 
nucleic acid amplification test) was developed to identify very minute amounts of PCA3 
mRNA from prostate cells shed in prostate urethra after prostatic massage and washed out 
immediately in first voided urine portion. Its estimated amount (number of copies) is 
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normalized to estimated number of PSA mRNA copies in the same sample and multiplied 
by 1000, resulting in PCA3 score. Test is known as Progensa PCA3 Assay (Gen-Probe Inc, 
San Diego, USA). Higher PCA3 score values indicate greater risk of presence of prostate 
cancer. Values from approximately 4 to 125 can be obtained, 35 being most often 
suggested cut-off, which, according to package insert has 53% sensitivity and 74% 
specificity for detection of prostate cancer on subsequent biopsy. Other cut-off opinions 
are continuously evaluated (Auprich et al., 2011). Although PCA3 mRNA theoretically 
could be measured in urine also with standard molecular-medicine techniques, which first 
isolate mRNA from cells in the sample and then perform RT-PCR, is this, due to very 
small amounts of PCA3 mRNA, very difficult and inconsistent, therefore dedicated 
patented method from Gen-Probe which uses direct amplification and avoids isolation 
step, has become standard. 
PCA3 use was suggested and marketed as help in biopsy decisions in previously negative 
prostate biopsies, in men with other risk factors (family history) and normal PSA values, in 
men with big prostates or other prostatic conditions where it is unclear whether high PSA is 
driven by cancer or other factor and in men on watchful waiting where high PCA3 score 
may indicate higher burden of disease.  
Use of consecutive PCA3 tests for follow up of biopsy candidates or men on watchful 
waiting was questioned due to high variability of results, if test is repeated in the same 
individual with low risk disease (Shikanov et al., 2011). 
Pre-biopsy PCA3 test results were evaluated together with PSA in relation to tumor 
characteristics in radical prostatectomy specimens (Vlaeminck-Guillem et al., 2011). It was 
found PCA3 score did not correlate with PSA and prostate volume. PCA3 score was also not 
related to Gleason score and pT stage. PCA3 did correlate with total tumor volume and 
index lesion volume. Further, multifocality was significantly correlated with PCA3. PCA3 
expression can be identified on malignant and benign prostate tissue samples, only quantity 
varies (Quiles et al., 2011). 
PCA3 test is, with many mentioned drawbacks and despite its high price, widely marketed 
and used in USA and EU. It seems sometimes may help in biopsy related decisions, but its 
role at present is still evolving.  
2.5 Family history, race, previous biopsy result 
Theoretically one may differentiate between familial (unpredictable clustering of disease in 
a family, slightly increased risk for offspring) and hereditary cancer (strong clustering 
pattern consistent with passage of a susceptibility gene via Mendelian inheritance) (Potter & 
Partin, 2000). Criteria for hereditary prostate cancer would be three or more first-degree 
relatives had prostate cancer, three successive generations had prostate cancer and where 
two relatives were affected at or before age 55. Despite identification of such families, their 
investigation has not resulted in such successful discoveries as in colon, ovary and breast 
cancers. In those classic hereditary cancers presence of a certain identifiable mutation with 
high probability predicts development of cancer in all affected offspring, which has resulted 
in formal screening programs for affected families and preventive surgery at early age. This 
is at present not known in prostate cancer.  
Familial history of prostate cancer increases risk. In a meta-analysis brother with prostate 
cancer increases risk 3.3 times, father 2.2 times, two first-degree relatives 5 times (Zeegers et 
al., 2003). 
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It is accepted increased risk due to family history should result in earlier start of screening 
(at age 40 or 35). Some risk calculators do use family history information to modify risk 
estimation (increased risk for presence of cancer in first degree relatives, this means father, 
brother or son), which may influence biopsy decision, if based on calculated risk. But apart 
from this, it does not tell us anything – PSA and other cut-offs for decision about biopsy are 
the same as in men without family history. Also procedures for biopsy, treatment and also 
treatment outcomes are the same between familial, hereditary and sporadic prostate cancer. 
There is no known 100% risk situations, which would provoke preventive removal of 
prostate, as is known for breast cancer, although people sometimes do ask for this. 
Recent research focused also on risk of prostate cancer in men whose family members have 
other forms of cancer. Men with first degree relative with breast cancer, who developed 
breast cancer at the age 35 or earlier, are at significantly increased risk of prostate cancer (5 
to 18 times in case of BRCA mutation) (Dite et al., 2010). Other cancers in family may also 
increase risk of prostate cancer (Izmirlian et al., 2011). 
Race is used in many prostate cancer risk calculators – African American race increases risk 
compared to Caucasians, Hispanic or Asian have decreased risk. But, the same as for family 
history, apart from earlier start of screening or a little different risk estimates from 
calculators, there are no other practical consequences of this fact at present.  
Previous negative biopsy decreases risk of positive subsequent biopsy. There are, however, 
two findings, which differ: PIN (=HGPIN – high grade prostatic intraepithelial neoplasia, 
low grade PIN was abandoned) and ASAP (atypical small acinar proliferation). HGPIN is 
most probable precursor of prostate cancer. There are structurally benign ducts and acini 
with abnormal secretory cells with prominent nucleoli (Schoenfield et al., 2007). HGPIN is a 
histological entity in itself, it is not cancer. ASAP indicates finding of small focus of structure 
in a 2-dimensional view, which is not large enough to satisfy criteria for cancer. It may 
represent only specific cut of top of benign acinus or PIN. One may define different 
characteristics under ASAP category, like adenosis, intraductal hyperplasia... which have in 
common that pathologist can not say for certain, whether they represent cancer or not. As 
ASAP may represent cancer, is was identified as predictor of positive repeat biopsy. 
Identification of multiple HGPIN in a biopsy specimen was also identified as predictor of 
positive repeat biopsy (Akhavan et al., 2007). Therefore, ASAP and HGPIN require 
consideration about repeat biopsies. ASAP may require immediate scheduling for repeat 
biopsy. HGPIN requires careful follow up and in most cases other criteria (PSA increase) 
cause repeat biopsy sooner or later (for example in 1-2 years time).  
2.6 Risk based strategies 
Different nomograms were developed, which can predict risk of positive biopsy. They take 
into account risk for age, family history, race, PSA and free PSA, digital rectal exam and 
some also for body mass index and even new decision aids, for example PCA3 and PHI.  
Nomograms have introduced new dimension in patient-physician pre-biopsy discussion. 
Need for individual's risk adjustment is illustrated by cardiology example. Do general 
practitioners and cardiologists decide whether one needs aspirin or statin on a single total 
cholesterol measurement (for example with result of 5.3 mmol/L, just above normal)? No. 
They measure HDL, LDL cholesterol, they ask for age, gender, blood pressure, smoking 
history. They consult nomograms and then decide whether statin drug is necessary (and 
reimbursed) or not. But urologists were dependent on a single PSA value? This has changed 
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with risk calculators availability. Using single PSA cutoff value would be the same as 
claiming for a man, who runs marathon, has normal blood pressure, normal BMI, is a 
non-smoker, his parents lived till age 100 and has cholesterol of 5.3 mmol/L – to be at 
high risk for cardiac event because his cholesterol is elevated (above 5.2). Using single 
PSA value for biopsy decision would be the same as claiming for an overweight (BMI 30), 
sedentary man, heavy smoker, on three anti-hypertensive medications whose parents 
both died of cardiac event, because his cholesterol is 5.1 mmol/L (just normal) – not to be 
at risk for cardiac event. Everyone can clearly see ridiculosity, absurdity of such approach 
in cardiology – but we in urology use PSA as single dichotomous variable in our prostate 
biopsy decisions?! Risk calculators allow us to tell men with any PSA value their 
individual chances for biopsy outcome. Calculators report risk for high grade (Gleason 7 
or more) and overall cancer probability. For example if calculator predicts 6% chance of 
significant prostate cancer (Gleason 7 or more) and 26% of overall cancer risk, we should 
tell patient his chance of being without cancer at present is approximately 74% (100-26), 
he has 6% chance of finding important high risk cancer and he has approximately 20% 
(26-6) chance biopsy would find cancer which may not be clinically important at present 
(but maybe in the future) and we would have to deal with this. If we explain this way, 
most men can and do take their own decision, whatever it is (to proceed with biopsy or 
continue PSA follow up). 
Using risk calculators often surprises us with values one would not expect. For example use 
Sunnybroke Prostate risk calculator (see below) and take 75 years old healthy Caucasian 
male with PSA of 3.9, %free PSA 22%, IPSS 9, in a good health (for example upper 25% of his 
generation), no family history for prostate cancer and negative DRE. He has more than 15 
years of life expectancy, 39% risk of prostate cancer and 20% risk of having at present high 
grade prostate cancer (Gleason 7 or more). 20% risk of high grade cancer and more than 15 
years of life expectancy - would you suggest a biopsy? 
At present (june 2011), one of the most modern (can take into account PCA3, p2PSA...) pre-
biopsy nomograms is available from UT Health Science Center, San Antonio, head Ian 
Thompson (http://deb.uthscsa.edu/URORiskCalc/Pages/calcs.jsp). Opponents of his 
calculator state it has good estimation of overall cancer risk, but underestimates high risk 
cancers. Large urology collection of nomograms, also many pre-biopsy nomograms 
including estimation of biopsy risks, are available from Pierre Karakiewicz, Cancer 
Prognostics and Health Outcomes Unit from University of Montreal Health Centre, Canada 
(www.nomograms.org). Calculators derived from European Randomized study of 
Screening for Prostate Cancer (Fritz Schroeder) are available at SWOP Prostate Cancer 
Research Fundation: http://www.prostatecancer-riskcalculator.com/via.html. Useful, 
simple and modern (more accurate high risk cancers estimation) pre-biopsy nomogram is 
available from SunnyBrook Health Sciences Centre, Toronto: http://sunnybrook.ca/ 
content/?page=OCC_prostateCalc. 
Different nonograms, for example taking into account 3D biopsy approach (Sakura et al., 
2011) are being developed and published constantly. Also, comparisons (Oliveira et al., 
2011) and evaluations (Ngo et al., 2011) are permanently performed and published. When 
using nomograms, one should be aware of their limitations (Vickers & Cronin, 2010). 
NCCN guidelines on prostate cancer early detection not require nomogram use, follow in 
part risk adapted approach, cover most “before biopsy” issues, are regularly updated and 
modern. They are available freely after registration from www.nccn.org. 
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3. Methods of biopsy 
Prostate cancer was in the past diagnosed most often using histology from transurethral 
resection, which was performed for local complications of prostate cancer or merely BPH. 
As it became clear such diagnosis is most often too late, makes subsequent radical surgical 
treatment more difficult and as PSA become available, biopsy had become diagnostic 
method of choice. At first, it was finger guided, blind. With development of transrectal 
ultrasound (trus – transrectal ultrasound guided prostate biopsy) and coupling it to 18G 
needle, Pandora box of prostate cancer was opened. 
3.1 Transrectal or transperineal approach? 
Most prostate biopsies around the world are performed transrectally, as this naturally 
developed from transrectal finger guided approach, is cheaper, simpler, does not need 
any analgesia or anaesthesia (although it is highly recommended, see section 4.3). 
Transperineal approach does need at least local anaesthesia. On same occasions, like post 
surgical amputation of the rectum, if it is sutured, transperineal biopsy (or transgluteal) 
may be the only way. However, such biopsy is guided by US probe on the perineum or in 
the urethra or more often by CT or MRI, which is not the way transperineal biopsy is 
performed regularly. Regular transperineal biopsy is performed using probe in the rectum 
and needle is advanced through the skin above rectal opening. Transperineal approach 
has similarity with the way some treatments are performed (brachytherapy...). Treatment 
templates may be used for biopsy which may guide biopsy needle to a specific part of 
prostate, which is seen as potentially more effective and with better gain. Recently, 
stereotactic templates (even motorized and computer guided) have become available also 
for transrectal prostate sampling – mechanically assisted 3D TRUS guided biopsy system 
(Megwalu et al., 2008). Supporters of transperineal approach suggest transperineally 
apical and anterior parts of the prostate may be better accessed compared to transrectal 
approach. For those reasons, studies were designed to compare yields of transrectal 
versus transperineal biopsy approach in primary 12-core and saturation 20-core schemes 
(Hara et al., 2008; Abdollah et al., 2011). Those studies uniformly showed no difference in 
cancer yields. However, this has not convinced proponents of transperineal approach. In 
regions, where transperineal approach was used routinely and claimed to be better 
compared to transrectal (for example some parts of Italy), they are only lately 
discovering prostate biopsy with end-fire probe (Galosi et al., 2010). Due to technical 
development of ultrasound equipment, some manufacturers (also very respectful one), 
were using side-fire probe with needle “through-the-probe” technology. This was 
proved to be inferior (Chin et al., 2009) in comparison to end-fire biopsy approach (see 
below). Therefore comparison of perineal to side-fire transrectal approach is not 
appropriate. Combination of transrectal and transperineal approach has also been used 
and described, aiming at gaining best from both approaches and maximizing cancer 
detection rate (Kawakami et al., 2007). 
Transrectal approach is recommended for routine primary and also saturation prostate 
biopsy. On rare occasions, where stereotactic guidance may be needed, decision on 
approach depends on availability of equipment. At present, equipment for transperineal 
stereotactic approach is more often available and more widespread, due to its use for 
brachytherapy (and different other new experimental approaches, such as cryotherapy or 
photodynamic therapy), compared to new and only limited availability of transrectal 
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computer and motor guided tools for prostate biopsy. Therefore, transperineal biopsy may 
be method of choice in selected cases. 
3.2 Transrectal ultrasound probe 
After analogue ultrasound probes have settled to history, electronic probes prevailed. Rotating 
mechanical sector probes have not gained popularity in the past. Present standard is electronic 
multi-element transducer - array. They come in two configurations. Side-fire probes have 
longitudinal transducer and take biopsies in longitudinal sections – sagittal plane, while end-
fire probes have curved array detector and allow biopsies to be taken also in transverse plane. 
In the past, Bruel and Kjaer and Kretz offered for prostate biopsy primarily side-fire probes 
and this was subjectively seen as better approach compared to end-fire probes (vaginal 
probes), used “secondarily” also for prostate biopsies. However, end-fire proponents build 
hypothesis better detection rate to be expected with end-fire sampling in transverse plane due 
to ability to direct needle more towards lateral part of the peripheral zone, where most tumors 
arise. This hypothesis was at first tested and confirmed for sextant biopsy in PSA range 4-10 
(Paul et al., 2004). This issue was challenged again in 2009, hypothesising end-fire probe has 
more oblique angled trajectory allowing better peripheral sampling (Ching et al., 2009). To 
reach anterior gland and apex in longitudinal plane, side-fire probe should be turned a lot and 
moved in a way which often causes pain as moves point of entry of the needle below dentate 
line of the rectum. End-fire probe allows better manipulation and targeting desired areas of 
prostate. Hypothesis was confirmed in their study, finding significantly better detection rate 
overall in the end-fire group compared to side-fire group and better detection in side-fire 
group for biopsies with more than 8 cores (8-12, 13-19 and 20 and more) and all PSA ranges 
(below 2.5, 2.5-4, 4-10 and more than 10) (Ching et al., 2009)  
Later, side-fire probes were often bi-planar, therefore allowing better orientation in the 
prostate, if one views it in two planes and offering choice between end-fire or side-fire 
biopsy guide. At present, interest has moved from purely end-fire or side-fire biopsy 
towards combined biopsy opinions and probe designs are now aiming further at 3-plane, 3D 
imaging and computer guidance... Biplanar probes have become standard equipment also 
because linear longitudinal array on the probe is necessary for transperineal prostate 
procedures guidance, while end-fire part is used for standard transrectal biopsy. Ideally, 
one should have the ability to use biplanar probe, but probably prefer end-fire setting for 
taking most biopsy cores.  
As history is repeating and revealing again in many aspects of human life, new TargetScan 
device (Envisioneering Medical Technologies, St. Louis, MO, USA) uses mechanical sector 
probe with single rotating element, applying it in “side-fire” configuration, but with needle, 
which bends, thus overcoming drawbacks from side-fire systems (Taneja, 2006). 
3.3 Biopsy needle 
Form, length, thickness, shape of biopsy needle, as everything regarding prostate biopsy, is 
being constantly challenged. It seems at present thickness of the needle is settled to 18G, 
needles are side-notch, true-cut, straight with stroke length of 22 mm. 
But it was not always so – aspiration biopsy (cytological biopsy) was around and well not so 
many years ago (Gustafsson et al., 1990). Length of the needle may not seem important at 
first sight, but for systematic sampling of all areas of big prostates, standard needle length 
may become limiting factor, as it may simply not be possible to advance needle from biopsy 
guide into the prostate enough to get sampling of all desired areas in a big or a bit 
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differently formed prostate. For example, TargetScan (Envisoneering) declares needle 
movement of 2.2 cm (standard for most biopsy guns, but not all) and possibility of needle 
protruding 2 cm from tip of biopsy guide before firing – together 42 mm of needle 
penetration. This is a description of a dedicated “robotic” system. In every day life, where 
ultrasound system and needle guide are one thing, hospital's supply for needles another and 
hospital's selection of biopsy-guns third issue, this should be considered, measured and 
perhaps some longer needles acquired for bigger prostates. Many other variants of needle 
characteristics were evaluated. Regarding stroke length, 33 mm end-cut was proposed (Dogan 
et al., 2005) by some, others proposed 29 mm side-notch instead of 22 mm (Fink et al., 2005). It 
is obvious longer is better and at least 22 mm should be used instead of old 15 mm, which was 
used at introduction of now obsolete sextant biopsy scheme (Hodge et al., 1989). Also 
thickness of needle was questioned – 18G (1.27 mm) was compared to thinner needles (0.9 mm 
(20G), 0.8 mm and 0.7 mm(22G)) – this old study found 0.9 mm may be acceptable (Norberg et 
al., 1994) – however it is not used in practice today. More recent studies evaluated thickness of 
needles again – non-ferromagnetic titanium needles were evaluated for quality of yield in 
comparison to standard needles – 16G (1.65 mm) titanium needle was found to provide 
samples of good quality and better compared to 18G regular (Franiel et al., 2006). However, 
also for MRI guided puncture, commercially available product is 18G needle (TSK, Japan) with 
characteristics comparable to regular needles. 
Until recently, only straight needles were in wide use. This creates problem with 
accessibility (see section 3.2). Recent machine for stereotactic trus biopsy Targetscan aims to 
overcome this problem with new pliable needle, which bends and allows good approach to 
most sites in the prostate in side-fire configuration. 
3.4 Image guidance 
In the beginning of transrectal prostate ultrasound era, large efforts were made attempting 
to recognize cancerous areas of prostate on gray ultrasound picture. Although hypoechoic 
lesions were identified as important (Terris et al., 1991) and we still lean toward specifically 
sampling hypoechoic areas as suspect in our every-day prostate biopsy work, we can not 
rely on them. After color doppler ultrasound was introduced, suspect areas were proposed 
to be the ones, which have higher or disorganized blood flow. Many studies have confirmed 
better sampling with the help of doppler or color flow imaging. However, presentation of 
subtly disorganized prostate vasculature and blood flow in potential cancer foci is very 
delicate and very dependent on sonographist, so only highly specialized individuals were 
and are able to put theory into practice. They are still trying to improve visualization of 
vasculature, either with ultrasound contrast or with other pharmacological agents, but other 
three presently available imaging techniques seem more promising as they may be more 
standardized and therefore easier for every urologist or radiologist, who, in a hurry and 
overwhelmed with other everyday work, perform mass of prostate biopsy burden: 
elastography, ANNA C-TRUS and HistoScanning.  
3.4.1 Role of MRI  
Magnetic resonance imaging with different modalities has established its role in prostate 
cancer imaging. Apart from T1 and T2 weighted images (Jager et al., 1996), which are not 
enough, multi-modal approach, like diffusion weighted imaging and dynamic contrast 
enhanced imaging was found necessary to identify tumor suspicious regions. Role of 
endorectal coil, although sometimes debated (for example for 3T may not be so important as 
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for 1.5T), seems also well established (Comet-Batlle et al., 2003). Tumor suspicious regions 
are found in different proportions, depending on criteria and number of different imaging 
modalities applied and can reach up to 98% even in post-trus-negative biopsy setting. After 
tumor suspicious regions are identified, sampling is needed.  
The easiest approach would be image fusion to trus picture, which is moving from 
development phase (Hu et al., 2010) and in some centers already represents routine practice 
(for example Heidelberg, Germany). Two systems are in development: transrectal Artemis - 
Eigen, Grass Valley, CA, USA (Natarajan et al., 2011) and transperineal BiopSee - MedCom, 
Darmstadt, Germany (Hadaschik et al., 2011). Incidental reports show identification and 
confirmation of cancer in patients with previously negative ANNA C-TURS biopsy, 
however, at present there are no studies which would compare any of the mentioned 
techniques and show individual strengths and indications. 
Some researchers perform MRI examination with plastic simulator of endorectal probe in-
situ to simulate deformation expected during trus biopsy setting (Ukimura et al., 2010). 
Others perform 3D ultrasound imaging and use electromagnetic positioning device to 
perform biopsies (Turkbey et al., 2011).  
Straightforward use of MRI would be MRI guided biopsy of MRI identified suspicious 
regions of prostate. Although at present available only in few institutions, this may very 
soon become more widespread as technology, procedure and equipment seem more and 
more ready for prime time (Roethke et al., 2011). Two independent retrospective series, 
performed with 1.5T or 3T magnets, from Netherlands (Hambrock et al., 2010) and from 
Germany (Roethke et al., 2011), report 52% and 58% (of patients with tumour suspicious 
regions identified) of positive MRI-guided biopsies after previous negative trus guided 
prostate biopsies.  
3.4.2 ANNA C-TRUS and HistoScanning 
Idea about reflected ultrasound wave analysis, which should reveal more data than can be 
seen just with naked eye, is old. There were and are still experiments taking place in 
developing algorithms of data analysis. Most often prostate is evaluated with transrectal 
ultrasound before radical prostatectomy and pictures are saved. After radical 
prostatectomy, histological sections of prostate with known areas of cancer and benign 
tissue are correlated with saved ultrasound data. Aim is to allow identification of cancer 
regions on ultrasound before biopsy or surgery. There may be many usages – 
HistoScanning is evaluated for prediction of Gleason score, volume of cancer, number and 
localization of cancer foci, prediction of location of cancer focus in relation to 
neurovascular bundle and in relation to prostate borders – all those data may be useful 
not only for decision to proceed or postpone biopsy and to guide biopsy, but also for pre- 
and peri-operative or other treatment planning.  
ANNA C-TRUS is a method, which analyzes typical transrectal ultrasound pictures of 
prostate in transversal plane (for example 5, on sections, where one normally takes biopsy 
cores). Pictures can be taken with any digital US scanner. Pictures are then sent, 
uncompressed (using either .tif, .bmp or .png format), using internet, to the provider. After 
analysis, suspect areas are marked on pictures and urologist repeats examination, this time 
taking samples from areas marked. All data available about this method seem at present still 
from the inventor and copyright holder of the technique, prof. Loch from Flensburg, they 
seem at present not independently evaluated. From author's report in 2010, it seems C-TRUS 
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ANNA technique detected 66 cancers, taking up to 6 cores in a series of 132 patients with 
previous negative prostate biopsy. Series included 62 patients with previous 1 negative 
biopsy, 41 with previous 2 negative biopsies, 18 with 3 negative biopsies, 6 with 4 negative 
biopsies and 5 with previous more negative biopsies (5-6) (Loch, 2010). This indicates 50% 
positive biopsy in a setting where lower numbers would be obviously expected, but data are 
not clear which part of the C-TRUS ANNA positive biopsies belongs to group of only one 
previous negative biopsy, some of them with only 6 cores, and which was percentage in a 
subgroup of patients with more negative biopsies. Method is commercially available from 
Fresenius Kabi Deutschland, Bad Homburg and costs in 2010 without tax (VAT) 
approximately 378 eur per use (one set of pictures analysis – one patient).  
Prostatic HistoScanning was developed proprietary by company AMD, Waterloo, Belgium 
in cooperation with B/K ultrasound manufacturer. According to company's web site 
(accessed in April 2011), it is commercially available in EU and Canada and awaits FDA 
approval for US. First it was aimed as “triage test for men deemed to be at risk for prostate 
cancer and who wish to avoid prostate biopsy” (Braeckman et al., 2008). Later it seems they 
realized getting rid of biopsy is at present not attainable goal and they focused on 
improving sampling of the prostate at biopsy (Braeckman et al., 2008). It seems method was 
developed by comparing raw ultrasound data from prostates before biopsy to histological 
results of patients, positive for cancer, who underwent radical prostatectomy. In this way it 
seems development was similar to ANNA C-TRUS, each using own mathematical modeling 
for differentiation between benign and malign areas of prostate. However, AMD's 
HistoScann uses in a way “more straightforward” data, in a technical sense – but it needs 
specific B/K ultrasound machine and specific probe and is limited regarding other US 
manufacturer's data. In the community, availability of proper US machines for addition of 
HistoScann technology is limited. Advantage, compared to C-TRUS ANNA is in data 
analysis and processing in a “black box”, which is for AMD's HistoScanning on site, while 
with C-TRUS ANNA one has to send data (over internet) to central facility and wait for 
analysis, therefore ultrasound prostate examination and biopsy can not be performed the 
same day, while HistoScann allows this. How often algorithms are changed and which are 
better, has not been evaluated yet although both systems are already commercially available 
in Europe and are, as such, competitors.  
Some specific claims about HistoScanning were challenged in the letter to the editor of BJU 
(Aigner & Frauscher, 2009), objecting name of the method and questioning resolution and 
ability of ultrasound to detect small tumor foci. In response, authors admit some limitations 
of their method, specifically lower quality of signal and therefore potentially less reliable 
analysis in case of dense calcifications in the prostate or for analyzing anterior component of 
a very large prostate. They compare it with MRI claiming there is wider availability or US 
compared to MRI. It is at present not true – MRI is available in a lot of hospitals, endorectal 
coils are single use, however, specific B/K ultrasound machine with particular probe and 
motorized machine for rectal probe guiding and AMD's “black box” are not available and 
seem at present more costly compared to MRI examination. Advantage of all ultrasound 
approaches compared to MRI approaches lies in assumption of ultrasound picture to be 
easier for use in subsequent sample acquisition. With the expected development of 
programs for US – MRI picture fusion, this advantage of pure-ultrasound approach may 
disappear. Question which is better or are all those methods (MRI (T-2, DW and 
spectroscopy), elastography, C-TRUS ANNA and HistoScanning) comparable or perhaps 
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they may supplement each other, will become important source of research endeavours in 
the future. HistoScanning manufacturer intends to use the technology also for other cancers, 
like ovary, thyroid and breast, which may be advantageous as prostate diagnosis may 
benefit from multidisciplinary team. On the other side, C-TRUS ANNA was developed by 
urologists for urologists, can be used in almost any setting (any digital ultrasound machine 
is good) and seems to have at present more peer reviewed data. HistoScanning is not aiming 
only towards prostate biopsy guidance, but also aims at other potentially useful predictions 
regarding prostate cancer and seems to have larger research base with groups from different 
countries (UK, Germany) who study its potential applications. Whether one or both 
techniques will stand the test of time and what role they will play remains open. 
3.4.3 Elastography 
Real time transrectal ultrasonoelastograpy of the prostate is aimed at discrimination 
between harder and softer areas of prostate tissue. MRI elastography technology was also 
developed (S. Li et al., 2011), but here only ultrasound is described. Back-scattered 
ultrasound waves are displaced with compression or decompression of tissue 
(approximately 2%), harder areas showing less displacement compared to softer (Salomon et 
al., 2008). Elastography is performed in real-time, at the time of biopsy – no previous 
transrectal ultrasound examination (as for C-TRUS ANNA) is necessary. By subjectively 
observing US elastography picture, operator aims at evaluating symmetry of stiffness, focal 
areas of hardness and persistence of stiffness with probe tilting, aiming at stiff nodule more 
than 5 mm in diameter and persistence of stiffness after probe tilting (Giurgiu et al., 2011). 
There are different scoring systems (Salomon et al., 2009), some focus on identifying smaller 
lesions and potentially showing increased sensitivity (Kamoi et al., 2008). Technique of 
elastography is still improving, better differentiation markers are being developed 
constantly (Zhang et al., 2011). Further, standardization of compression with idea of leaving 
this part to the machine is also in testing (Tsutsumi et al., 2010). Regarding companies which 
provide elastography equipment, most studies have been performed using Hitachi machine, 
which is commercially available for prostate applications and most tested, although other 
manufacturers also offer this technology. Among target-biopsy techniques elastograpy 
seems at present most widely spread as technology is also in use for breast cancer 
(primarily) and investment needed is only in US machine and probe, there are no per-
investigation charges as for C-TRUS ANNA. Elastography procedure is also much simpler 
compared to MRI-US fusion. Another advantage of elastography is in its compatibility with 
power/color doppler techniques for image guidance, which can be performed 
simultaneously, therefore gaining from two sources. There are quite a few published studies 
describing experience with prostate elastograpy from different parts of the world. Study 
results are positive and seem to support claims that elastography improves cancer detection 
rate. One of the very appealing studies, from USA, analyzed help of elastograpy in biopsy of 
men with PSA values between 1.25 and 4 and free/total PSA ratio less than 18% (Aigner et 
al., 2010). They were able to detect 24% of cancers using 5 cores with elastography guidance 
compared to 5.1% cancers using 10 systematic biopsies. Another study, from Romania, used 
and compared in the same set of patients gray scale, doppler and elastograpyh data 
(Giurgiu et al., 2011). They found, in a series of 65 patients and 43% of them with identified 
cancer on biopsy, sensitivity of elastograpy to be 68% and specificity 62%. Particularly 
promising was elastography in a subgroup of older than 70 years, where sensitivity 
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increased above 80% and lead authors to propose, if their results are further confirmed, in 
case of negative elastography and doppler, biopsy in this group and in relatively stable PSA, 
may be avoided. 
On recent demonstration of C-TRUS ANNA and elastography at the occasion of EAU 
Congress in Vienna (march 2011), where both techniques were exposed to a patient with 4 
previous negative biopsies and rising PSA, both techniques failed to find cancer in those two 
patients. This shows, as one can deduce from literature cited above: in approximately 50% of 
patients with suspicious characteristics (PSA) and previous negative biopsy, we are unable 
to find cancer at present. For how long? Will they develop cancer in the future? What is the 
right strategy to follow them? How they end? All those questions are important and need 
answers in future research.  
3.4.4 Color, power doppler 
Angiogenesis is important in development of cancer and increased vascularity was 
detected in tumors in general and in radical prostatectomy specimens, therefore use of 
ultrasound to detect those changes was proposed. Color doppler imaging estimates mean 
frequency shift of doppler signal to determine velocity and direction of flow. Power 
doppler shows total energy of the signal by integrating it, therefore resulting in sig`nal 
with homogenous background and more precise detection of smaller and low flow vessels 
(Remzi et al., 2004). Study of usefulness of power and color doppler for evaluation of 
hypoechoic lesions showed 80% sensitivity and 82% specificity for detecting prostate 
cancer (Cho et al., 2000). Standardized criteria for scoring different degrees and 
distributions of prostatic vascularity were developed and also subjective scales seem to 
work well (Mitterberger et al., 2010), however this points to high subjectivity of the 
method, which is its drawback. 
Power doppler was used for evaluation of peripheral prostatic capsular vessels, 
parenchymal vessels and vessels anastomosing with extraprostatic vessels (Sauvain et al., 
2003). Criteria for suspicion of cancer in this study were increase in number of intra-lesional 
vessels, disoriented vessels or verticalized vessels in peripheral gland, asymmetrical blood 
flow, mass effect on the intraprostatic perilesional vessels and vessels in peripheral margins. 
Analyzing all those criteria, they aimed at estimation of prostate cancer stage by dividing 
lesions into three groups: absent extracapsular involvement, undetermined extracapsular 
involvement and presumably present extracapsular involvement. In this series, 55.7% 
patients had cancer and sensitivity of power doppler ultrasound was claimed to be 92%, 
specificity 72% (compared to 88% and 58% for ultrasound only). Group with ultrasound 
estimated lack of extracapsular involvement had this found in final pathology in 11%, while 
group with ultrasound suspicious for extracapsular involvement had it confirmed in 87%. 
Authors (Sauvain et al., 2003) conclude power doppler ultrasound improves accuracy of 
ultrasound imaging in the diagnosis of cancer, can increase detection rate, optimize number 
of biopsy cores and also predict extracapsular invasion by identification of capsule 
perforating vessels. 
When using ultrasound for evaluation of minor differences in prostate blood flow between 
cancerous and benign areas, many factors can interfere with the results – for example 
position of the patient – it was shown left decubitus position caused flow asymmetry 
resulting in more biopsies directed toward left side without improving detection rate 
(Halpern et al., 2002).  
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Different pharmaceutical interventions were proposed to increase difference between 
cancer and benign tissue: improved view with contrast agent, increased flow with 
phosphodiesterase inhibitor (vardenafil) (Morelli et al., 2011) or decreased flow with 5-
alpha reductase inhibitor or combination of 5-alpha reductase inhibitor with contrast 
agent (Mitterberger et al., 2008).  
Contrast enhanced transrectal prostate ultrasound was extensively evaluated in multiple 
research projects (Wink et al., 2008). Microbubbles act as additional reflectors in bloodstream 
and increase sensitivity of color and power doppler imaging. Newer techniques, for 
example harmonic imaging, were also tested. Use of ultrasound contrast agent is associated 
with only minimal side effects, like alterations in taste, flush or pain at the injection site. 
However, it costs additional money for contrast. It should be performed in 4 minutes after 
contrast injection (half life of bubbles). Further drawback is strong operator-dependence of 
the technique. Contrast enhanced ultrasound enables visualisation of prostate cancer (in up 
to 78% of cases), but sensitivity and specificity are not enough to avoid systematic biopsies. 
Targeted biopsies using this technique are claimed to allow lower number of cores per 
session without decrease in detection rate (Wink et al., 2008). 
Use of 5-alpha reductase inhibitor was proposed in two staged approach: first color/power 
doppler evaluation of prostate is followed by 1-3 week of dutasteride and than reevaluation 
and biopsy guided to areas, where vascular signals have not decreased after treatment. 
Additional sextant systematic sample was also taken. Researchers claimed increased yield in 
targeted cores (20%) compared to sextant cores (8%) (Ives et al., 2005). 
3.5 Biopsy schemes and number of cores 
After finger guided biopsy strategies were replaced with ultrasound guided, it soon became 
clear (group around dr. Stamey, Stanford) 6 cores, taken in a systematic fashion, finds more 
cancer than aiming at hypo-echoic areas or randomly (Hodge et al., 1989). Standard 
approach, which hold for more than 10 years, was established: six cores were taken in 
parasagittal plane, one at the base, one mid-gland and one at apex. However, patients with 
negative biopsies and still suspicious for cancer, had repeat biopsies, which were almost as 
often positive as first biopsy – therefore it was obvious the system was not perfect. Aim 
should be – perform biopsy – if it is negative, then there is no cancer. Reality was – perform 
classic sextant scheme biopsy – if it is negative, then there is almost the same probability for 
cancer as before biopsy. So – search has begun for improvement of systematic biopsy scheme 
(mainly searching for optimal number of cores and location of cores) and this search has not 
settled yet. As this text aims at the future, not past, only some examples will be pointed out. 
Inadequacy of sextant scheme was proven many times, for example (Norberg et al., 1997) and 
also recent larger and longer retrospective data analyzes still turn to this question, for example 
regarding sextant biopsy's ability to predict unilateral disease (Mayes et al., 2011). First it 
became clear biopsies should be directed more laterally in the peripheral zone of the prostate 
(Eskew et al., 1997). Later, it seemed transitional zone inclusion may improve cancer detection, 
however this was abandoned for initial biopsy, because of inferior gain from transitional zone 
directed cores compared to more sampling toward far lateral mid-gland and anterior-apical 
areas. A lot of cancers are located on anterior horn of prostate. With repeat biopsy, of course, 
anterior transitional zone is also sampled (Chun et al., 2010). Innumerous analyzes have 
shown – more cores – more cancer. Prostate size has a role (Taneja, 2006). Nomogram was 
developed to optimize number of cores needed in relation to prostate size – so called Vienna 
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nomogram (Remzi et al., 2005), as it is obvious higher number of cores gives better sampling 
and improves detection. Later, while some still questioned Vienna nomogram's usefulness 
(Lecuona & Heyns, 2010), it became obvious number of biopsy detected cancers is related to 
sampling density, which is a quotient between prostate size and number of cores taken. A lot 
of nomograms, which predict probability of positive prostate biopsy, take sampling density 
into account (Chun et al., 2007). Regarding number of cores, it went up from six at first to 
eight, later ten, later twelve (a lot of us still using this number at present for majority of 
patients for first biopsy), fifteen, eighteen... up to twenty-one (Guichard et al., 2007) core per 
biopsy session. This number seems to be highest present routine extended systematic biopsy 
scheme, simply because twenty-four or more cores is called saturation biopsy (Ahyai et al., 
2010). Many have also argued they were unable to increase their cancer detection rate after 
increasing number of cores from for example 12 to 18. This underscores importance not only of 
number, but also direction of cores.  
3.6 Free hand systematic biopsy, targeted biopsy, prostatic mapping or combination 
Goal of prostate biopsy is not only to find “some” cancer in the prostate, as it was in the 
past. Now, it has not only to provide representative sample of DIL (dominant intraprostatic 
lesion), but also to show all “important” cancer areas in the prostate, describe precisely 
where they are and ensure other regions are cancer free. This is in contrast to efforts of 
targeted biopsies which claim they may reduce pain and burden of biopsy by reducing 
number of cores.  
Prostate-mapping biopsy approaches, for example TargetScann, have different approach – 
they aim at precisely sampling predefined sections of prostate with larger number of cores. 
Electronic doppler ultrasound probes are becoming increasingly complex and sensitive to 
detect blood flow signals in the prostate to help guiding biopsy. TargetScan's device 
ultrasound probe is sector and at present can not be used for image-guided approaches, but 
seems to provide relatively reliable results regarding prostate mapping, which is very 
important for all targeted therapy approaches (Andriole et al., 2007). “Robotic” probes 
(ultrasound systems, which are just inserted into rectum by physician and then guided by 
pressing buttons, are being developed also by other manufacturers.  
We have therefore a mix of partly competing, some probably complementary and some 
excluding technologies aiming at improving prostate cancer detection and staging. Which 
will find its way into every-day practice and to what extent, remains open. It seems at 
present repeat biopsy yield is about 20%-40% and targeted biopsy methods claim, in repeat, 
previously negative setting, yield of 50%. All those new approaches need evaluation and 
confirmation. One way may be showing significantly better performance of targeted or 
mapping approaches compared to prediction of nomograms for repeat biopsy setting (Chun 
et al., 2007).  
Overall, it seems at present first biopsy should be 10-18 laterally directed cores (depending 
on prostate size, for prostates larger than 50 ml minimum 14). Targeted biopsy only, with 
less than 6 cores, may generally not be appropriate for the first biopsy, as it is far from 100% 
and we need to assess whole prostate. 
For second and later biopsies, as targeted opinions are becoming more and more 
widespread and therefore accessible and are not untested technical glitches any more, we 
may in 2011 suggest any of the recently developed opinions, depending on local availability, 
as follows. 
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1. If no targeted approach is available and also there is lack of funds (for example for C-
TRUS ANNA), transrectal saturation biopsy may be performed and probably it may be 
useful to perform MRI or choline PET-CT to help identifying suspicious areas. 
2. If equipment and local expertise allow, any of the targeted biopsy methods (for example 
C-TRUS ANNA or others) should be used. 
3. Stereotactic biopsy (TargetScan or transperineal) is definitely better opinion compared 
to free-hand saturation biopsy. Stereotactic approach may also be suggested after 
diagnosis, regarding watchful waiting or minimally invasive therapies planning.  
4. Periprocedural considerations 
Prostate biopsy is potentially dangerous and painful procedure. Preparation, informed 
consent with explanation of possible complications, administration of proper antibiotic 
prophylaxis, policy on anticoagulant and antiaggregation medications and pain 
management should be standardized and followed in every patient. 
4.1 Enema and needle handling 
Although bowel preparation with enema or clear fluids are not necessary before biopsy 
(Zaytoun et al., 2011) or no statistically significant increase in complication rate was 
identified with change of regimen (Ruddick et al., 2011), some still claim less septic 
complications with enema use (Kanjanawongdeengam et al., 2009) or even with the way 
enema is properly administrated (Huang et al., 2006). In the light of modern approaches to 
bowel surgery, extensive enemas really look outdated, but it is obvious rectum should be 
empty before biopsy and suppository in the evening or morning before biopsy seems very 
reasonable and appropriate. The future with development of resistant bacteria may even 
bring back old classical methods (cleaning rectum with povidone iodine enema or simply 
povidone iodine suppository), but at present this is not standard. 
Question of role of re-inserting “dirty” needle. Most of us use one needle for the whole 
procedure (all cores). Some (Kisner in Maribor, Slovenia) have insisted on using sterilized 
needle with every core, others studied cleaning needle with povidone iodine solution 
during procedure (Koc et al., 2010). No decrease in complications was shown with those 
techniques.  
4.2 Antibiotics 
Most common causative organism for infectious complications following trus prostate 
biopsy is E.coli. Antibiotic prophylaxis is necessary and guidelines from European and 
American urological societies have been issued and regulate this question, although 
different antibiotic regimens are used in practice. Guidelines are freely accessible on web 
from the issuing societies (EAU and AUA) and provide also extensive lists of literature, 
which will therefore not be reviewed again here.  
EAU guidelines (www.uroweb.org, 2010 edition) recommend antimicrobial prophylaxis, 
but admit choice of regimens remains debatable. They list studies which suggest single 
doses for low-risk patients and remark, prolonged course should be considered for high-risk 
patients. Expected patogens are Enterobacteriaceae and possibly also anaerobes. 
Recommended antibiotics are fluoroquinolons, TMP+SMX and metronidazole with question 
mark (no evidence).  
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AUA guidelines (www.auanet.org, 2008 edition, reviewed 2010) also confirm prophylaxis is 
indicated in all patients as randomized controlled trials have confirmed significantly lower 
rates of complications in antibiotic groups. They also claim single dose may be adequate. 
A lot depends on local antibiotic resistance patterns. For example, if TMP+SMX regimen is 
not used even for non-complicated urinary tract infections in one area, one would not use it 
for prostate biopsy prophylaxis either. One can never predict for sure future development of 
antibiotic resistance. Therefore, constant vigilance is needed and monitoring rates of 
infectious complications is necessary. Special attention should focus on repeat biopsies and 
this setting may sometimes deserve different antibiotic scheme or previous culture and 
susceptibility analysis. Later may be performed in two ways – patients with catheters or 
other urinary tract insertions may be screened using urine culture (Bruyere et al., 2010), but 
all who need screening should have their stools sample cultured for resistant strains. 
Resistant strains do occur and may significantly contribute to complications (Liss et al., 
2011). Due to high probability of E.coli resistance to quinolones in cases of patients returning 
to hospital after prostate biopsy with quinolone prophylaxis, it is wise to use another 
antibiotic before cultures are known (although it seems obvious, people do often get 
prescribed flouroquinolone again). If there is no or low risk for ESBL, cephalosporines 
(probably third generation) may be the best initial guess (Zaytoun et al., 2011). 
Although single dose is claimed useful, in our and many other situations most patients can 
be considered not low risk regarding infectious risk classifications (more than 65 years of 
age, concomitant diseases, like diabetes and lower urinary tract symptoms, incomplete 
bladder emptying). Therefore typical scheme (as we use it and others, for example (Campos-
Fernandes et al., 2009), uses ciprofloxacin 500 mg twice daily started before biopsy and 
continued for three days. It was shown to decrease rate of complications after biopsy 
(Schaeffer et al., 2007). As every single infectious complication, even most minor, requiring 
any health-service contact, even only consultation, is seen as a big problem and aim is to 
avoid any complication, there are many patients who probably benefit from short course 
and not single dose antibiotic and this may be further reason why urologists are reluctant in 
accepting single dose only approach.  
Metronidazol is added in some centers routinely, but most do not use it at present. 
However, it might be useful for specific patients, with specific predisposing conditions and 
in combination with other antibiotics (for example cephalosporins, although subjective 
experience shows more complications with their use for this purpose), when 
flouroquinolone resistance or intolerance is present. 
Instead of 1-2 hour prior to procedure fluoroquinolone orally, same use parenteral 
aminogylcoside (gentamicin or amikacin) or aminopenicilline with betalactamase inhibitor 
(co-amoxiclav) at the time of biopsy, which is followed by oral antibiotic (often 
fluoroquinolone, but also others) at home. This scheme is used in some centers and may be 
helpful when compliance with oral regimen prior to biopsy is questionable or for allergy 
and non-tolerance to quinolones or in areas with high resistance to quinolones (Kehinde et 
al., 2008). Combination of periprocedural oral dose of ciprofloxacine with iv dose of 
gentamicin may be method of choice for single dose regimens.  
Additional important recent problem regarding fluoroquinolones was finding 
significantly different serum concentrations of active drug comparing different generic 
manufacturers (Kehinde et al., 2010). Apart from probable reason for higher complication 
rate, substandard antibiotics preparations also contribute to resistance development as 
longer courses are needed and as a consequence low concentrations of drug are present in 
the environment for longer time.  
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4.3 Pain control 
Only 11% of urologists in US used local anesthesia to reduce pain during trus biopsy in 2002 
(Davis et al. 2002). At the time, a strong appeal from one of the most distinguished opinion 
leaders favored local anesthesia (Soloway, 2003). Thereafter, guidelines (AUA, EAU, NCCN) 
all recommended or even mandated (AUA) local pain medication use during this 
procedure. Intrarectal application of eutectic cream or lidocaine jelly may decrease pain as 
some anesthetic agent may reach site of pain with diffusion, but it is variable and is 
considered not adequate. Pain during transrectal prostate biopsy is caused by two sources.  
First source of pain is probe insertion and presence and movement of probe in the anal 
canal during biopsy. This can be ameliorated with slow and gentle dilation and local 
lidocaine jelly or EMLA cream, but other measures for relaxation of sphincter were also 
used with success and are available – local glyceryl trinitrate oinment or spray or local 2% 
diltiazem or 0,2% - 0,5% nifedipine oinment. Using gylceryl trinitrate oinment, headache 
was noted as side effect in 10% of patients – dose was 2 mg (McCabe et al., 2007). It 
remains open, whether lower dose of spray (0,4 mg/activation) would reach same effect 
with less side effects. 
Second source of pain during trus biopsy is related to nerves in prostate capsule and 
neurovascular bundles. After a lot of research (for example (Scattoni et al., 2010)) it seems 
accepted injection of 2x 5 ml (each side) of 1% lidocaine most appropriately reduces pain. 
Site of injection may be at the base (basolateral periprostatic nerve plexus area, described 
also as prostate-vesicular junction injections) or at the apex. Debate where to inject sill 
continues. Quality control suggested for standard technique of periprostatic block, 
observation of hypoechoic nodule (“wheal”) formation on the site of injection is needed. It 
was shown least pain (best effect) was observed, when hypoechoic nodule formed after 
injection on both sides (Obek et al., 2006). Regarding injectable agents, for potential 
lidocaine allergic patients, tramadol has significant local anesthetic properties and is 
universally available and it has also been studied in this setting (Seckiner et al., 2011).  
Addition of oral medication, either for sedation or for additional pain relief may be also 
helpful in selected patients.  
5. Complications 
Generally, complications are: hematuria (13%-74%), hemospermia (30%), blood at stools 
(1%), pain (4%), nausea (up to 1%), fever (up to 1%), epididymitis (up to 1%), infection 
which needs hospitalization (0,3%). Most feared complication is sepsis.  
Another important complication is bleeding. Patients can bleed from rectum, they can 
observe hematuria or hemospermia. Bleeding is most often self limiting and settle in a few 
days. Rarely significant issues (bladder tamponade or significant rectal bleeding) would 
occur. Such occasions would of course necessitate hospitalization or use of appropriate 
standard measurements for treatment. Bleeding may be more significant with anticoagulant 
treatment. Warfarin is stopped well before biopsy and patient is covered with low molecular 
weight heparin. Low dose acetylsalicylic acid (aspirin) may be continued, although some 
still recommend a drug holiday for a few days (till bleeding settles). There are no experience 
with newer antithrombotic drugs (for example dabigatran and other factor Xa inhibitors) 
and it is generally suggested to be avoided during prostate biopsy (changed to low-
molecular weight heparin, the same as for warfarin). Clopidogrel should also be stopped, 
although there is a report claiming 15% of urologists to continue with both clopidogrel or 
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warfarin (Brewster et al., 2010). This is not advisable, except aspirin and low molecular 
weight haparin, all other similarly working medications should be stopped before biopsy. 
Regarding clopidogrel, explicit agreement and consent between patient, his cardiologist and 
urologist may result in exception, but extreme caution is needed.  
Immediate complications, like fainting, diaphoresis should be controlled by adequate local 
pain control. It is also not advisable for patients to be completely fasted. 
Rate of complications increases with time. Most important and frequent seem infectious 
complications. Reasons for increasing rates of complications may be increasing numbers of 
cores per procedure or increased antibiotic resistance (Nam et al., 2010).  
Long term complications of prostate biopsy would be development of pain syndromes or 
problems with erectile function, which was described recently (Klein et al., 2010). This 
reminds us that indefinitely repeating biopsies and increasing number of cores per biopsy 
may not be the best way forward. Selective, targeted approaches must be taken seriously, as 
prostate biopsy is not without its consequences. 
6. Chemopreventive stategies 
Inhibitors of 5-alpha reductase (5ARI), finasteride or dutasteride, may be used short term to 
decrease blood flow in the prostate before biopsy (as described at the end of section 3.4.4). 
Further, it is speculated their longer term use (6 months or more) may decrease proportion 
of benign prostate in a whole gland and in this way increase chances for prostate cancer 
detection on prostate biopsy. It may also reduce development of low grade cancer. One 
possible strategy for use of 5ARI inhibitors is prescription of drug after first or second 
negative biopsy and then regular follow up of PSA. PSA is expected to decrease. Trigger for 
repeat biopsy is any increase of PSA above nadir or if PSA value under 5ARI is above 40% of 
initial PSA value. Described approach was recently retrospectively evaluated in abstract 
form, using REDUCE data (Roobol et al., 2011). However, a proportion of prostate cancers 
do progress (for example on watchful waiting) without this fact reflecting in increase of 
PSA. Therefore a possibility of prostate cancer progression (in patients on 5ARI treatment or 
without) while PSA values would not increase is a serious concern and needs further 
research. We should always be aware, none of our methods is 100% successful. 
7. Conclusion 
Future of prostate biopsy will be interesting, a lot of new ideas and technologies are 
competing at present and it remains open which will, in the end, dominate the market and 
our every-day practice.  
Although new targeted technologies, either ultrasound or magnetic resonance, may improve 
detection and sampling and reduce need for increasing number of cores and repeat biopsy 
sessions, none seem at present nearing 100% sensitivity or specificity. At present, 
approximately 50% positive biopsy rate is expected in repeat biopsy setting using either C-
TRUS ANNA or MRI-guided or MRI-US picture fusion guided biopsy.  
As burden of biopsies may increase dramatically in the near future (as explained above - 
(Quon et al., 2011)) further increases in complexity and technological demands may not be 
able to satisfy mass biopsy needs. Prostate biopsy is not very demanding procedure, 
potential harms and problems for patients do exist, but are not nearly as large as for 
different forms of prostate cancer treatments. Therefore, such a breakthrough as happened 
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in the field of prostate surgery regarding robotic assisted prostatectomy, is not expected. 
Perhaps we may expect in the near future coexistence of many different biopsy opinions and 
methods, which are showing comparable results, the same situation as developed for 
surgical treatment of prostate cancer, where robotic, laparoscopic and open radical 
prostatectomies progressed to the level, where all show same good results (Eden et al., 
2011). It seems present simple system – transrectal probe with 10-20 samples per session, 
with some additional help of ultrasound picture analysis and systematic sampling systems 
or not - is here to stay and will be main working horse for enormous number of prostate 
biopsies which are expected to be performed in the next decade. New markers (PCA3 and 
p2PSA) will complement PSA and free PSA in decisions about second and further repeat 
biopsies. At the same time different US and MRI methods, tailored to different patients 
needs, wishes and different predicted treatment modalities will be available to supplement 
basic approach when needed and will develop further.  
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